JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 84.2%

Neg 0% Neu 0% Pos 84.2%

JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $115 to $125.